Bicocca Open Archive

Logo unimib boa
CIARDULLO, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.913
AS - Asia 5.922
EU - Europa 4.116
SA - Sud America 1.029
Continente sconosciuto - Info sul continente non disponibili 369
AF - Africa 189
OC - Oceania 43
Totale 20.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.369
SG - Singapore 2.104
IT - Italia 1.524
CN - Cina 1.134
HK - Hong Kong 761
BR - Brasile 746
VN - Vietnam 717
RU - Federazione Russa 617
DE - Germania 475
CA - Canada 426
SE - Svezia 309
IE - Irlanda 271
BD - Bangladesh 253
GB - Regno Unito 240
IN - India 211
FR - Francia 162
KR - Corea 126
ID - Indonesia 114
AR - Argentina 108
NL - Olanda 89
FI - Finlandia 77
IQ - Iraq 77
JP - Giappone 59
ZA - Sudafrica 55
TR - Turchia 54
ES - Italia 52
PK - Pakistan 51
MX - Messico 50
PL - Polonia 50
CH - Svizzera 49
SA - Arabia Saudita 48
UA - Ucraina 48
CO - Colombia 47
AU - Australia 41
EC - Ecuador 41
PH - Filippine 36
EG - Egitto 33
AT - Austria 31
VE - Venezuela 27
UZ - Uzbekistan 22
BE - Belgio 21
MA - Marocco 18
DK - Danimarca 17
MY - Malesia 17
JO - Giordania 16
TW - Taiwan 15
CL - Cile 14
IR - Iran 14
PY - Paraguay 14
AE - Emirati Arabi Uniti 13
DZ - Algeria 13
PT - Portogallo 12
RO - Romania 12
KE - Kenya 11
NP - Nepal 11
OM - Oman 11
UY - Uruguay 11
CR - Costa Rica 10
PA - Panama 10
PE - Perù 10
BG - Bulgaria 9
TH - Thailandia 9
BO - Bolivia 8
CZ - Repubblica Ceca 8
ET - Etiopia 8
GT - Guatemala 8
HN - Honduras 8
LT - Lituania 8
NG - Nigeria 8
IL - Israele 7
JM - Giamaica 7
KZ - Kazakistan 7
NI - Nicaragua 7
TN - Tunisia 7
ZM - Zambia 7
AZ - Azerbaigian 6
EE - Estonia 6
SN - Senegal 6
DO - Repubblica Dominicana 5
GR - Grecia 5
LB - Libano 5
AL - Albania 4
BY - Bielorussia 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
PS - Palestinian Territory 4
AO - Angola 3
BW - Botswana 3
HR - Croazia 3
NO - Norvegia 3
ZW - Zimbabwe 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
BS - Bahamas 2
CG - Congo 2
CY - Cipro 2
GD - Grenada 2
HU - Ungheria 2
MU - Mauritius 2
Totale 20.176
Salva come PNG Salva come JPEG
Città #
Singapore 1.206
Ashburn 957
Hong Kong 734
Ann Arbor 702
San Jose 630
Milan 465
Santa Clara 372
New York 303
Frankfurt am Main 287
Chicago 274
Toronto 267
Dublin 260
Hefei 238
Los Angeles 235
Dallas 218
Ho Chi Minh City 214
Beijing 203
Chandler 201
Council Bluffs 188
Fairfield 175
Hanoi 158
Rome 125
Seoul 105
The Dalles 104
Wilmington 104
Princeton 99
Seattle 99
Houston 98
Lauterbourg 86
Boardman 81
London 72
Woodbridge 72
Jakarta 71
Cambridge 69
Columbus 67
São Paulo 67
Atlanta 61
Altamura 58
Buffalo 57
Moscow 57
Phoenix 56
Munich 54
Shanghai 52
Montreal 50
Helsinki 48
Lawrence 48
San Francisco 46
Zurich 44
Brooklyn 43
Denver 42
Orem 42
San Diego 42
Warsaw 34
Da Nang 32
Figino 32
Tokyo 32
Baghdad 31
Bari 31
Haiphong 30
Nuremberg 27
Boston 24
Dong Ket 24
Guangzhou 24
Monza 24
Philadelphia 24
Naples 22
Rio de Janeiro 22
Mumbai 21
Riyadh 21
Turin 21
Biên Hòa 20
Charlotte 20
Nanjing 20
Stockholm 20
Tashkent 20
Bologna 19
Chennai 19
Kent 19
Miami 19
Quito 19
Washington 19
Dhaka 18
Hải Dương 18
Johannesburg 18
Lappeenranta 18
Brussels 17
Pittsburgh 17
Florence 16
Mexico City 16
Sydney 16
Brasília 15
Kocaeli 15
Manchester 15
Porto Alegre 15
Pune 15
Vienna 15
Amman 14
Amsterdam 14
Jeddah 14
Salt Lake City 14
Totale 11.396
Salva come PNG Salva come JPEG
Nome #
Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy 883
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction 676
Differential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States 495
Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? 487
Exploring the landscape of steatotic liver disease in the general US population 461
Metabolic dysfunction-associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi-centre cross-sectional study 437
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting 394
Endocrinology and Metabolic Diseases (Including Diabetes) 374
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes 286
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions 271
Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes 258
Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes 253
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes 252
Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence 251
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes 245
Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients 237
Preferences, Expectations and Attitudes on Basal Insulin from Patient–Physician–Payer Perspective: A Multi-stakeholder Survey by the Italian Diabetes Society (ITA4P Study) 233
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 230
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes 229
Seasonal variation in estimated cardiovascular risk in patients with type 2 diabetes 229
Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study 228
Time trends in liver-related mortality in people with and without diabetes: Results from a population based study 224
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes 222
Authors' response to Guo, Wei et al. 220
Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population 219
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis 217
Development of a new model of insulin sensitivity in patients with type 2 diabetes and association with mortality 213
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 213
Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort 212
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications 212
Lack of awareness of liver organ damage in patients with type 2 diabetes 211
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment 207
Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus 207
Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD 206
NAIF: A novel artificial intelligence-based tool for accurate diagnosis of stage F3/F4 liver fibrosis in the general adult population, validated with three external datasets 206
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study 204
Baseline TSH levels and short-term weight loss after different procedures of bariatric surgery 204
Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017–2018 National Health and Nutrition Examination Survey 203
Medication Use Before and After Different Bariatric Surgery Procedures: Results from a Population-Based Cohort Study 201
Authors' reply to Zou et al 201
Evaluating the Prognostic Value of the Triglyceride–Glucose Index in Different Populations: A Critical Analysis 197
Metabolic and psychological features are associated with weight loss 12 months after sleeve gastrectomy 196
Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population 195
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population 190
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting 190
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes 189
Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories 188
Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population 187
Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy 186
Impact of the duration of type 2 diabetes on the screening for nonal- coholic fatty liver disease and advanced fibrosis 184
Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study 182
An unexpected bilateral mass after total thyroidectomy 181
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 180
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents 179
Serum neurofilament light chain levels are associated with all-cause mortality in the general US population 179
Sex-related association of NAFLD and liver fibrosis with body fat distribution in the general US population 178
Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study 176
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 176
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 174
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016 172
Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines 172
Risk stratification tools for heart failure in the diabetes clinic 171
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes 169
Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition 164
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population 163
Low 25 (OH) vitamin D levels are associated with increased prevalence of NAFLD and significant liver fibrosis 161
Readily Available Index of Insulin Sensitivity Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes 160
Authors' reply to Shang et al. 160
NAFLD and liver fibrosis are not associated with reduced femoral bone mineral density in the general US population 160
Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease 159
Glycated albumin is associated with all-cause and cardiovascular mortality among U.S. adults with and without diabetes: A retrospective cohort study 157
Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. women 157
Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general U.S. population 156
Steatotic Liver Disease Phenotypes in the United States: The Impact of Alcohol Consumption Assessment 156
Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis 155
Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis 151
Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence 150
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease 150
Liver stiffness is associated with all-cause mortality in patients with NAFLD: A systematic review and meta-analysis 146
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States 144
Reply [to: Use of FibroScan–AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US...] 140
Global multi-stakeholder endorsement of the MAFLD definition 139
Twenty-year trends in heart failure among U.S. adults, 1999–2018: The growing impact of obesity and diabetes 138
Comment on “An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD” 137
Non-invasive scores of liver fibrosis in morbidly obese patients 135
Reply to "Liver fibrosis assessed by transient elastography and albuminuria" 135
The MAFLD‐MASLD debate: Does cardiovascular risk prediction define the winner? 131
Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999-2016 130
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes and association with micro- and macrovascular complications 130
Control of Blood Glucose and Cardiovascular Risk Profile 130
Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs 127
Advances in fibrosis biomarkers in nonalcoholic fatty liver disease 124
Prevalence of Noninvasively Detected Clinically Significant Portal Hypertension Among U.S. Adults With and Without Diabetes 120
Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes 119
Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD 118
Silent threats: how NAFLD and hypertension team up in young adults, and the role of sex 111
Qualitative Properties of Circulating Fatty Acids Are Associated With MASLD: A Cross-Sectional Study From the NHANES Database 100
Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases 95
Assessing Europe's policy readiness to confront the MASLD/MASH public health threat 71
Totale 20.581
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.868
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.868
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022437 0 0 0 42 25 52 28 35 50 62 44 99
2022/20231.240 146 226 123 108 92 228 40 71 87 26 58 35
2023/20241.236 89 42 84 102 112 216 166 53 91 53 34 194
2024/20254.090 215 404 309 233 331 220 288 121 343 517 427 682
2025/20269.024 883 717 637 902 859 410 1.182 438 640 698 893 765
2026/20273.001 686 674 941 700 0 0 0 0 0 0 0 0
Totale 20.581